<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141008</url>
  </required_header>
  <id_info>
    <org_study_id>HM20009338</org_study_id>
    <nct_id>NCT03141008</nct_id>
  </id_info>
  <brief_title>Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet</brief_title>
  <official_title>Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Obesity Treatment Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the impact of a Low Carbohydrate Ketogenic Diet (LCKD) weight loss program and
      compare to the standard of care program established for patients with Non-Alcoholic Fatty
      Liver Disease (NAFLD) on: (1) Liver fat and liver stiffness scores, (2) lipid profile and
      insulin sensitivity; and (3) depression scores and quality of life, and (4) Cardiometabolic
      measures such as cardiopulmonary exercise test (CPET) and transthoracic echocardiogram (TTE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective pilot pragmatic trial will investigate the role of a LCKD weight loss
      program for obese patients (BMI ≥30 kg/m2) and compare it to the group of known obese NAFLD
      patients who receive dietetic counseling as part of their standard of care in a dedicated
      NAFLD program. All participants (n=50) will be recruited at Virginia Commonwealth University
      (VCU).

      Patients will do initial paperwork including

      Questionnaires QOL, eating disorder screen, depression screen:

      QOL, eating disorder screen and depression screen.

      Labwork:

      Data will be collected from routine care labwork to include a fasting cholesterol panel,
      insulin, A1c and comprehensive panel (if they have not received these labs in the preceding 3
      months), and at 6 and 12 months. A1c will be collected at 3,6,9 months as well (if A1c &gt;/=7),
      or just additionally at 6 months if A1c &lt;7

      Study labs will be collected:

      Blood at 0, 3, 6 and 12 months Urine, stool and saliva at 0, 1, 3 and 12 months

      Fibroscan will be done at 0, 3, 6 and 12 months

      Echo/CPET testing and Room calorimetry will be offered and the patients agreeing to do this
      will have them done at 0, 3 and 12 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fat and stiffness scores compared to control group as well as intrasubject trend</measure>
    <time_frame>0, 3, 6, 12 months</time_frame>
    <description>Performed with a fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiometabolic labs</measure>
    <time_frame>0, 6, 12 months (3 and 9 months for A1c if &gt;7</time_frame>
    <description>Lipids, A1c, Insulin, comprehensive metabolic panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other specialized testing</measure>
    <time_frame>Only to a few of the eligible patients, 0, 3, 12 months</time_frame>
    <description>Echo, cardiopulmonary exercise testing, room calorimetry</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <condition>Fatty Liver</condition>
  <condition>Ketogenic Dieting</condition>
  <arm_group>
    <arm_group_label>Ketogenic diet exposed group</arm_group_label>
    <description>Fibroscan changes with different diets:
Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD diet exposed group</arm_group_label>
    <description>Fibroscan changes with different diets:
Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fibroscan changes with different diets</intervention_name>
    <description>Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens</description>
    <arm_group_label>Ketogenic diet exposed group</arm_group_label>
    <arm_group_label>NAFLD diet exposed group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      routine care labs will be done on patients including Comprehensive metabolic panel, A1c,
      lipids and insulin levels. Additional specimens will be taken for serum, urine, stool and
      saliva. These will be collected at time points 0, (additional timepoint of 1 month for
      saliva, stool and urine), 3 months, 6 months and 12 months.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50 people from the PI's weight loss clinic using an a priori ketogenic diet. Will be
        compared with 50 people from a NAFLD clinic using a low calorie, low fat diet.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria include patients aged 18 years and older, BMI ≥ 30, ALT
             (alanine transferase) &gt; 19 (female) and &gt; 30 (male) or radiographic evidence of
             hepatic parenchymal disease and seen in either the PIs weight loss clinic or a patient
             in the VCU NAFLD (non-alcoholic fatty liver disease) program.

        Exclusion Criteria:

          -  Patients will be excluded if they have known other liver disease such as viral
             hepatitis, autoimmune hepatitis, liver transplant, severely ill, weekly alcohol use
             (&gt;14 drinks in men and &gt;7 drinks in women), HIV, pregnant females, those&lt; 18 years,
             and prisoners.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Wolver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VCU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Wolver, MD</last_name>
    <phone>804 828-5148</phone>
    <email>swolver@vcu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Wolver, MD</last_name>
      <phone>804-828-5148</phone>
      <email>swolver@vcu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1513-20.e1. doi: 10.1016/j.cgh.2015.01.027. Epub 2015 Feb 3.</citation>
    <PMID>25661453</PMID>
  </reference>
  <reference>
    <citation>Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov;56(5):1741-50. doi: 10.1002/hep.25855.</citation>
    <PMID>22611040</PMID>
  </reference>
  <reference>
    <citation>Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016 Aug;65(2):425-43. doi: 10.1016/j.jhep.2016.04.005. Epub 2016 Jun 1. Review.</citation>
    <PMID>27091791</PMID>
  </reference>
  <reference>
    <citation>Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol. 2013 Dec;108(12):1861-8. doi: 10.1038/ajg.2013.349. Epub 2013 Oct 8.</citation>
    <PMID>24100261</PMID>
  </reference>
  <reference>
    <citation>Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44. doi: 10.1038/nrgastro.2013.41. Epub 2013 Mar 19. Review.</citation>
    <PMID>23507799</PMID>
  </reference>
  <reference>
    <citation>Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015 May;61(5):1547-54. doi: 10.1002/hep.27368. Epub 2015 Mar 23.</citation>
    <PMID>25125077</PMID>
  </reference>
  <reference>
    <citation>Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-Hubert I, Rousselet MC, Calès P, de Lédinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016 Sep;65(3):570-8. doi: 10.1016/j.jhep.2016.04.023. Epub 2016 May 2.</citation>
    <PMID>27151181</PMID>
  </reference>
  <reference>
    <citation>Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014 Jun;59(6):2188-95. doi: 10.1002/hep.26986. Epub 2014 Apr 25.</citation>
    <PMID>24375711</PMID>
  </reference>
  <reference>
    <citation>Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002 Jul 2;137(1):1-10.</citation>
    <PMID>12093239</PMID>
  </reference>
  <reference>
    <citation>Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016 Sep;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013. Epub 2016 May 17.</citation>
    <PMID>27212244</PMID>
  </reference>
  <reference>
    <citation>Nagano M, Sasaki H, Kumagai S. Association of cardiorespiratory fitness with elevated hepatic enzyme and liver fat in Japanese patients with impaired glucose tolerance and type 2 diabetes mellitus. J Sports Sci Med. 2010 Sep 1;9(3):405-10. eCollection 2010.</citation>
    <PMID>24149634</PMID>
  </reference>
  <results_reference>
    <citation>Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370. Review. Erratum in: JAMA. 2015 Oct 13;314(14):1521.</citation>
    <PMID>26057287</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketosis</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

